ORXOY Orexo AB Sponsored ADRs

Orexo AB (publ), a specialty pharmaceutical company, develops products based on proprietary drug delivery technology. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. Orexo AB (publ) was founded in 1995 and is headquartered in Uppsala, Sweden. This is an ADR of a company whose stock trades outside of the U.S. as the symbol SS:ORX.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$2.30    OTCQX
As of 07/01/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Sweden
Country of incorporation:  Sweden
IPO date:  09/09/2013
Outstanding shares:  34,710,639
Average volume:  99
Market cap:   $79,834,470
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy